Nervous Disorder TRIZ Cases

Introducing Nurr1 and Foxa2 into neurons or glia inhibits tau accumulation, aggregation, and tangles to slow Alzheimer's progression.

A single bicistronic AAV delivers HEXA and HEXB together to overcome low CNS co-infection and restore functional HexA expression.

A COX-2 inhibitor plus antiviral regimen targets herpes-linked cytokine activity to relieve fatigue, cognitive dysfunction, and pain in long COVID.

Targeting NAA levels in the CNS helps shift neurodegenerative metabolism back toward glycolysis, improving myelin production and function.

Multiple crystalline forms of a glucosylceramide synthase inhibitor are characterized to improve chemical stability, reproducibility, and drug quality.

Disrupting HS-TREM2 complex formation or activating TREM2 promotes amyloid-beta clearance and may slow neurodegenerative disease progression.

High-purity expanded NK cells use irradiated feeder cells and cytokines to improve Alzheimer's treatment while reducing impurities and adverse reactions.

CED infusion of rAAV into the striatum expands cortical and striatal expression, improving delivery reach for neurologic therapy.

A solvent and terpene boosted dicarboxylic acid ester composition improves analgesic delivery while lowering glucose levels and inhibiting hemolysis.

Crystalline tryptamine solvates and baeocystin forms improve molecular weight accuracy, API stability, and dosing reliability in pharmaceutical use.

Novel bicyclic Kv7.2/3 activators improve antiepileptic activity while avoiding the blue-skin discoloration seen with retigabine.

Modified fatty acid analogs target cannabinoid and PPAR receptors to treat pain and cognitive impairment without opioid addiction risk.

Engineered HER2-TfR multispecific antibodies use transferrin receptor transcytosis to cross the BBB with improved safety and pharmacokinetics.

Engineered M13 phages display Aβ42 motifs to detect toxic oligomers and fibrils, cross the blood-brain barrier, and inhibit aggregation.

A BoNT/A-B receptor fusion extends toxin retention in affected neck muscles, reducing injection frequency while maintaining safer dosing.

An antibody-guided extracellular vesicle crosses the blood-brain barrier to deliver drugs to dopamine neurons while limiting off-target brain exposure.

A 5HT3 antagonist such as ondansetron reduces pramipexole GI side effects, enabling higher tolerated doses for major depression.

A modular PROTAC recruits E3 ligase to ubiquitinate and degrade PIKfyve, addressing resistance and low efficacy of inhibitor-based treatment.

A bifunctional tricyclic PROTAC recruits E3 ligase to degrade IRAK4, overcoming mutation-driven resistance and expanding target coverage.

These compounds recruit E3 ligase to lower Cyclin E1 in cancer cells while limiting GSPT1 degradation and normal-tissue toxicity.

A fatty acid amide-modified K-opioid receptor agonist extends half-life to reduce dosing frequency while relieving pruritus and postoperative pain.

A nucleic acid factor boosts cell stemness and proliferation, enabling ethical reprogramming, mass culture, and stronger regenerative therapy.

Fc and variable-region amino acid changes enable pH-dependent C1s binding, stronger FcRn recycling, and lower-dose complement inhibition.

An anti-DAT antibody carried by extracellular vesicles crosses the blood-brain barrier to target dopamine neurons and reduce alpha-synuclein buildup.

A solvent-terpene dicarboxylic acid ester composition boosts permeation, disrupts lipid rafts, and helps reduce pain and blood glucose.

A specific L. rhamnosus CNCM I-3690 oral composition reduces anxiety and stress in humans without requiring extremely long-term use.

Novel 3-heteroaryl pyrrolidine and piperidine agonists target orexin receptors to improve sleep-wake and related neurological functions.

Perrottetinene-like compounds such as CBD-PET and CBD-PET-OH show anti-seizure activity across generalized and myoclonic seizure models.

Stabilizing agents, surfactants, salts, and sugars help AAV formulations retain potency, limit adsorption, and reduce particles during storage.

Targeting HTR1D with selective agonists offers a pharmacologic route to reduce addiction cravings and withdrawal symptoms.

Binding GFAP with combretastatin-A4 or analogs reduces CNS protein aggregates, helping delay neurodegenerative disease onset and progression.

Stable (2R,6R)-hydroxynorketamine salt crystals use defined polymorphs to speed antidepressant action while reducing CNS effects and hygroscopicity.

Using Lactobacillus paracasei to modulate the gut-brain axis, this case shows a nutritional route to support mental health with fewer side effects.

Using Schwann cell conditioned media, OM-MSCs are expanded into Schwann-like cells to support peripheral nerve repair without donor nerve harvest.

Combining beta-hydroxybutyrate and acetoacetate in salt, ester, and acid forms helps sustain ketosis longer with fewer side effects.

Chemically modified MAPT siRNA conjugates use antigen-binding proteins to cross the blood-brain barrier and lower tau in CNS tissue.

CRET probes remove excitation-light limits in NIR imaging, improving sensitive amyloid aggregate detection in vitro and in vivo.

Tailored peptide analogues balance GLP-1 and glucagon activity to drive weight loss and metabolic benefits without significant nausea.

Targeting TDRP with antibodies helps reduce anxiety-like behavior in autoimmune disease while preserving immunomodulatory treatment benefits.

Cyclized dye-peptide conjugates improve CNS delivery of TrkB/TrkC modulators, supporting neural regeneration, recovery, and imaging.

Superstructured Au-pX gold clusters reduce oxidative stress and DNA damage while improving mitochondrial function in Friedreich's ataxia.

A carbamate compound composition targets diabetic and chemotherapy-induced peripheral neuropathy when existing pain relief is often insufficient.

Camelid-derived CD70 antibodies improve low-copy tumour cell binding while enabling effective CD70/CD27 interaction blocking.

Targeting GRIN2B in indirect pathway neurons reduces levodopa-induced dyskinesia while preserving levodopa motor benefit.

Ex vivo cytokine-activated PBMCs help restore glucose, lipid, and hormonal balance in type 2 diabetes and related disorders.

A targeted chimeric protein repairs the blood-brain barrier, activates AKT survival signaling, and limits oxidative stroke damage.

Controlled nasal spray droplets improve PDE inhibitor deposition and nasal cavity coverage for more effective memory loss treatment.

Mamaki leaf, fruit, and seed polyphenols help maintain cerebral function while promoting neurogenesis and clearing disease-causing proteins.

Combining an anti-CDH6 antibody-drug conjugate with an HIF-2α inhibitor boosts antitumor activity while simplifying multi-agent cancer treatment.

Structural changes to amyloid-targeting compounds improve plasma exposure consistency and GI tolerability while reducing amyloid aggregates.